EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling

Naruhisa Ota iD, Christopher W Davies iD, Jing Kang, Donghong Yan iD, Alexis Scherl iD, Anne Wong iD, Ryan Cook, Xun Tao iD, Debra Dunlap, Sha Klabunde, Priscilla Mantik, Vishnu Mohanan und 13 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2501635122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Naruhisa Ota und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology Discovery, Genentech, South San Francisco, CA 94080. Hauptthemen laut MEDLINE: Interleukin-23, Single-Domain Antibodies, Signal Transduction, Peptide Hydrolases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin (IL)-23 is a validated therapeutic target in inflammatory bowel disease. While antibodies targeting IL23 demonstrate clinical efficacy, they face challenges such as high costs, safety risks, and the necessity of parenteral administration. Here, we present a workflow to simultaneously enhance the affinity and protease stability of an inhibitory anti-IL23R VHH for oral use. Cocrystal structure analysis reveals that the anti-IL23R VHH employs both CDR and framework residues to achieve picomolar affinity for IL23R. The engineered VHH remains stable for over 8 h in intestinal fluid and 24 h in fecal samples. Oral administration of this VHH achieves deep pathway inhibition in a murine colitis model. Furthermore, a single pill provides sustained IL23R inhibition in nonhuman primate blood for over 24 h. With high potency, gut stability, high production yield, and favorable drug-like properties, oral VHHs offer a promising approach for inflammatory bowel diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-23Single-Domain AntibodiesSignal TransductionPeptide HydrolasesAnimalsMiceHumansAdministration, OralProtein EngineeringColitisInflammatory Bowel Diseases

Stichwörter der Autor:innen

antibodyimmunologyoral deliveryprotein engineering

Substanzen

Interleukin-23Single-Domain AntibodiesPeptide Hydrolases

Autor:innen und Institutionen

  • Department of Immunology Discovery, Genentech, South San Francisco, CA 94080.
  • Antibody Engineering, Genentech, South San Francisco, CA 94080.
  • Translational Immunology, Genentech, South San Francisco, CA 94080.
  • Pathology, Genentech, South San Francisco, CA 94080.
  • Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA 94080.
  • Preclinical and Translational Pharmacokinetics, Genentech, South San Francisco, CA 94080.

ORCID-Profile: Naruhisa Ota, Christopher W Davies, Donghong Yan, Alexis Scherl, Anne Wong, Xun Tao, WeiYu Lin, Kelly M Storek, James R Kiefer, James T Koerber

Förderung

  • NIGMS NIH HHS
  • NIH HHS

Zitieren

APA

Ota, N., Davies, C. W., Kang, J., Yan, D., Scherl, A., Wong, A., Cook, R., Tao, X., Dunlap, D., Klabunde, S., Mantik, P., Mohanan, V., Lin, W., McBride, J., Sadekar, S., Storek, K. M., Lupardus, P., Ye, Z., Ackerly Wallweber, H., …, & Koerber, J. T. (2025). Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2501635122

Vancouver

Ota N, Davies CW, Kang J, Yan D, Scherl A, Wong A, et al. Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2501635122

BibTeX
@article{Ota2025,
  author = {Ota, Naruhisa and Davies, Christopher W and Kang, Jing and Yan, Donghong and Scherl, Alexis and Wong, Anne and Cook, Ryan and Tao, Xun and Dunlap, Debra and Klabunde, Sha and Mantik, Priscilla and Mohanan, Vishnu and Lin, WeiYu and McBride, Jacqueline and Sadekar, Shraddha and Storek, Kelly M and Lupardus, Patrick and Ye, Zhengmao and Ackerly Wallweber, Heidi and Kiefer, James R and Xu, Min and Chan, Pamela and Nagapudi, Karthik and Yi, Tangsheng and Koerber, James T},
  title = {Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2501635122}
}
Kostenlos starten →